Multistrain Probiotics Supplement Alleviates Asthma Symptoms via Increasing Treg Cells Population: A Randomized, Double-Blind, Placebo-Controlled Trial

Abbasi-Dokht, Tannaz; Sadrifar, Sina; Forouzandeh, Sarvenaz; Malek, Farhad; Hemmati, Maral; Kokhaei, Parviz; Baharlou, Rasoul

doi:10.1159/000526739

Cited by 7 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple studies have also shown Treg cell percentage and their suppressive activity were significantly decreased in SARS-CoV-2 patients [ 33 ]. It has been suggested that TNF-α and IL-6 could reduce suppressive activity in Tregs by preventing of TGF-β and FoxP3 expression [ 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, Khoshmirsafa and colleagues found that IL-17, IL-6, and IL-10 were the risk factors for the progression of the disease [ 31 ]. In addition, Th2 and Th17 hyperactivation due to polyclonal activation possibly with superantigens led to high antibody titers and the creation of cytokine storms [ 34 , 38 ]. On the basis of these findings, lymphopenia and high expression of RORγt and GATA3 could be independent risk factors associated with COVID-19 severity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

T-Cell Immune Responses and Immunological Factors Associated with Coronavirus Disease 2019 Progression as Predictors for the Severity of the Disease in Hospitalized Patients

Abbasi-Dokht¹,

Vafaeinezhad²,

Khalesi³

et al. 2023

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

Introduction: The prevalence of coronavirus disease 2019 (COVID-19) has rapidly increased worldwide. More investigation is needed to progress toward understanding the exact role of immune responses in the pathology of the disease, leading to improved anticipation and treatment options. Methods: In the present study, we examined the relative expression of T-bet, GATA3, RORγt, and FoxP3 transcription factors as well as laboratory indicators in 79 hospitalized patients along with 20 healthy subjects as a control group. In order to make an exact comparison between various degrees of severity of disease, patients were divided into critical (n = 12) and severe (n = 67) groups. To evaluate the expression of genes of interest by performing real-time PCR, blood samples were obtained from each participant. Results: We found a significant increase in the expression of T-bet, GATA3, and RORγt and a reduction in the expression of FoxP3 in the critically ill patients compared to the severe and control groups. Also, we noticed that the GATA3 and RORγt expressions were elevated in the severe group in comparison with healthy subjects. Additionally, the GATA3 and RORγt expressions showed a positive correlation with elevation in CRP and hepatic enzyme concentration. Moreover, we observed that the GATA3 and RORγt expressions were the independent risk factors for the severity and outcome of COVID-19. Discussion: The present study showed that the overexpression of T-bet, GATA3, and RORγt, as well as a decrease in the FoxP3 expression was associated with the severity and fatal outcome of COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

T-Cell Immune Responses and Immunological Factors Associated with Coronavirus Disease 2019 Progression as Predictors for the Severity of the Disease in Hospitalized Patients

Abbasi-Dokht¹,

Vafaeinezhad²,

Khalesi³

et al. 2023

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

show abstract

“…93 Supplementation with a probiotic mixture of multiple Lactobacilli, B. longum, and Streptococcus thermophilus in adults with asthma resulted in an improvement of lung function, a reduction in several inflammatory markers and an increase in regulatory markers. [94][95][96] However, in longitudinal studies, supplementation with L. reuteri, L. rhamnosus, or B. lactis or a mix of Lactobacilli and Bifidobacteria to pregnant women in the last month of pregnancy, 3-6 months postpartum, and after birth to their newborns till 6 months to 2 years of age did not induce a difference in asthma incidence at school age. [97][98][99][100] In conclusion, the in vivo interventions described above only seem to influence asthma symptoms in children above 3 years and adults and do not prevent asthma development, when given during pregnancy and in newborns.…”

Section: Interventi On S Tud Ie Smentioning

confidence: 92%

“…A study in which 3–14 years old asthmatics were supplemented with a mixture of Lactobacillus and Bifidobacterium for 16 weeks found a reduction in asthma exacerbations 93 . Supplementation with a probiotic mixture of multiple Lactobacilli, B. longum , and Streptococcus thermophilus in adults with asthma resulted in an improvement of lung function, a reduction in several inflammatory markers and an increase in regulatory markers 94–96 . However, in longitudinal studies, supplementation with L. reuteri, L. rhamnosus , or B. lactis or a mix of Lactobacilli and Bifidobacteria to pregnant women in the last month of pregnancy, 3–6 months postpartum, and after birth to their newborns till 6 months to 2 years of age did not induce a difference in asthma incidence at school age 97–100 …”

Section: Intervention Studiesmentioning

confidence: 99%

Influence of the gut and airway microbiome on asthma development and disease

Smulders,

Van Der Schee,

Maitland‐Van Der Zee

et al. 2024

Pediatric Allergy Immunology

View full text Add to dashboard Cite

There are ample data to suggest that early‐life dysbiosis of both the gut and/or airway microbiome can predispose a child to develop along a trajectory toward asthma. Although individual studies show clear associations between dysbiosis and asthma development, it is less clear what (collection of) bacterial species is mechanistically responsible for the observed effects. This is partly due to issues related to the asthma diagnosis and the broad spectrum of anatomical sites, sample techniques, and analysis protocols that are used in different studies. Moreover, there is limited attention for potential differences in the genetics of individuals that would affect the outcome of the interaction between the environment and that individual. Despite these challenges, the first bacterial components were identified that are able to affect the transcriptional state of human cells, ergo the immune system. Such molecules could in the future be the basis for intervention studies that are now (necessarily) restricted to a limited number of bacterial species. For this transition, it might be prudent to develop an ex vivo human model of a local mucosal immune system to better and safer explore the impact of such molecules. With this approach, we might move beyond association toward understanding of causality.

show abstract

“…They have a potential role in the treatment of viral respiratory infections and influenza virus infections, as well as in the treatment of nervous system diseases (9). These effects may stem from the regulation of several potential mechanisms (10)(11)(12)(13)(14)(15)(16), including cell phenotype, endocrine factors, and signaling pathways (Table 1). For example, probiotics improve asthma symptoms and lung inflammation maybe through increasing Treg cells population and regulating TLR4/NF-kB signaling pathways, respectively.…”

Section: Introductionmentioning

confidence: 99%

Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

BackgroundMulti system symptoms such as gastrointestinal tract and respiratory tract exist in coronavirus disease 2019 (COVID-19) patients. There is a lack of reliable evidence to prove that probiotics are effective in improving these symptoms. In this study, we aimed to evaluate the efficacy of probiotics in meta-analysis.MethodsWe systematically searched PubMed, Embase, Web of Science, and Cochrane Library up to February 15, 2023. Randomized controlled trials or high quality retrospective studies comparing the efficacy of probiotics as supplementation with non-probiotics in improving symptoms for patients with COVID-19 were included. This meta-analysis assessed endpoints using Review Manager 5.3.ResultTen citations comprising 1198 patients with COVID-19 were included. The results showed that probiotics could increase the number of people with overall symptom improvement (RR = 1.62, 95% CI [1.10, 2.38], P = 0.01) and shorten the duration (days) of overall symptoms (MD = −1.26, 95% CI [−2.36, −0.16], P = 0.02). For the duration (days) of specific symptoms, probiotics could improve diarrhea (MD = −2.12, 95% CI [−2.41, −1.83], P < 0.00001), cough (MD = −2.21, 95% CI [-4.56, 0.13], P = 0.06) and shortness of breath (MD = −1.37, 95% CI [-2.22, −0.53], P = 0.001). Probiotics had no obvious effect on fever, headache and weakness. For inflammation, probiotics could effectively reduce C-reactive Protein (CRP) serum level (mg/L) (MD = −4.03, 95% CI [−5.12, −2.93], P < 0.00001). Regarding hospital stay (days), probiotics group was shorter than non-probiotics group (MD = −0.98, 95% CI [−1.95, −0.01], P = 0.05).ConclusionTo some extent probiotics could improve the overall symptoms, inflammatory reaction and shorten hospital stay of patients with COVID-19. Probiotics may improve gastrointestinal symptoms (such as improving intestinal flora and reducing the duration of diarrhea) and further improve respiratory symptoms through the gut-lung axis.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=398309, identifier: CRD42023398309.

show abstract

Multistrain Probiotics Supplement Alleviates Asthma Symptoms via Increasing Treg Cells Population: A Randomized, Double-Blind, Placebo-Controlled Trial

Cited by 7 publications

References 38 publications

T-Cell Immune Responses and Immunological Factors Associated with Coronavirus Disease 2019 Progression as Predictors for the Severity of the Disease in Hospitalized Patients

T-Cell Immune Responses and Immunological Factors Associated with Coronavirus Disease 2019 Progression as Predictors for the Severity of the Disease in Hospitalized Patients

Influence of the gut and airway microbiome on asthma development and disease

Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis

Contact Info

Product

Resources

About